Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Global Blood Therapeutics, Inc. - Common Stock (NQ: GBT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Global Blood Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Pfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal: Report
Pfizer Inc (NYSE: PFE) is reportedly in advanced talks to buy Global Blood Therapeutics Inc (NASDAQ: GBT) for about $5 billion, bolster its portfolio and pipeline. 
Via Benzinga
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Recap: Global Blood Therapeutics Q1 Earnings
Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share... 
Via Benzinga
Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session
Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday. 
Via Benzinga
Alibaba, MercadoLibre And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Via Benzinga
Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket
Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on Wednesday. 
Via Benzinga
Why Global Blood Therapeutics Stock Is Surging After Hours
Global Blood Therapeutics Inc (NASDAQ: GBT) shares are soaring in Wednesday's after-hours session following a report suggesting the company is attracting takeover interest. 
Via Benzinga
7 Small-Cap Growth Stocks With 1,000% Upside Potential
Here're 7 small-cap growth stocks with 1,000% upside potential. ACLS, AXSM, GBT, GPRO, HCAT, SKLZ, and VERU can make great investments. 
Via InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91. 
Via Investor's Business Daily
Looking Into Global Blood Therapeutics's Return On Capital Employed
According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of... 
Via Benzinga
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
The company is using a different approach to tackle the blood disease. 
Via Investor's Business Daily
7 No-Brainer Biotech Stocks to Add to Your Buy List
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. 
Via InvestorPlace
Global Blood Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42... 
Via Benzinga
Looking Into Global Blood Therapeutics's Return On Capital Employed
Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58... 
Via Benzinga
What 4 Analyst Ratings Have To Say About Global Blood Therapeutics
Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Recap: Global Blood Therapeutics Q4 Earnings
Global Blood Therapeutics (NASDAQ:GBT) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:05 PM. Here's what investors need to know about the announcement... 
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics
Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. 
Via Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
FDA Expands Use Of Global Blood' Sickle Cell Treatment To Kids Aged 4-12 Years
The FDA has granted accelerated approval to Global Blood Therapeutics Inc's (NASDAQ: GBT) supplemental application seeking approval for Oxbryta (voxelotor... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers GBS (NASDAQ:GBS 
Via Benzinga
Global Blood Raises $300M Via Convertible Debt Offering
Global Blood Therapeutics Inc (NASDAQ: GBT) priced $300 million Convertible Senior Notes due 2028 in a private offering. The offering size was increased from... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback